Chronic Plaque Psoriasis - Pipeline Review, H1 2015

Published: Jan, 2015 | Pages: 109 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Chronic Plaque Psoriasis - Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Chronic Plaque Psoriasis - Pipeline Review, H1 2015', provides an overview of the Chronic Plaque Psoriasis's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Chronic Plaque Psoriasis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Chronic Plaque Psoriasis and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Chronic Plaque Psoriasis
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in the therapeutics development for Chronic Plaque Psoriasis and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects 
- A review of the Chronic Plaque Psoriasis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Chronic Plaque Psoriasis pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Chronic Plaque Psoriasis
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Chronic Plaque Psoriasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

 Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Chronic Plaque Psoriasis Overview 8
Therapeutics Development 9
Pipeline Products for Chronic Plaque Psoriasis - Overview 9
Pipeline Products for Chronic Plaque Psoriasis - Comparative Analysis 10
Chronic Plaque Psoriasis - Therapeutics under Development by Companies 11
Chronic Plaque Psoriasis - Pipeline Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Chronic Plaque Psoriasis - Products under Development by Companies 15
Chronic Plaque Psoriasis - Companies Involved in Therapeutics Development 16
AbGenomics International, Inc. 16
Actelion Ltd 17
Almirall, S.A. 18
ApoPharma Inc. 19
Biotest AG 20
Boehringer Ingelheim GmbH 21
Can-Fite BioPharma Ltd. 22
Coherus BioSciences, Inc. 23
Covagen AG 24
Eli Lilly and Company 25
GlaxoSmithKline plc 26
Mitsubishi Tanabe Pharma Corporation 27
Novartis AG 28
OPKO Health, Inc. 29
Pfizer Inc. 30
Sandoz Inc. 31
Sun Pharmaceutical Industries Inc. 32
Takeda Pharmaceutical Company Limited 33
UCB S.A. 34
XenoPort, Inc. 35
Chronic Plaque Psoriasis - Therapeutics Assessment 36
Assessment by Monotherapy Products 36
Assessment by Target 37
Assessment by Mechanism of Action 39
Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
AbGn-168H - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
adalimumab biosimilar - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
baricitinib - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
BI-655066 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
certolizumab pegol - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
CF-101 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
CJM-112 - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
COVA-322 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
dimethyl fumarate - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
etanercept biosimilar - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
etanercept biosimilar - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
GSK-2831781 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
ixekizumab - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
lunacalcipol - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
MT-1303 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
namilumab - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
orilotimod - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
PF-06263276 - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
ponesimod - Drug Profile 75
Product Description 75
Mechanism of Action 75
R&D Progress 75
tildrakizumab - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
tregalizumab - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
XP-23829 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Chronic Plaque Psoriasis - Recent Pipeline Updates 80
Chronic Plaque Psoriasis - Dormant Projects 102
Chronic Plaque Psoriasis - Discontinued Products 103
Chronic Plaque Psoriasis - Product Development Milestones 104
Featured News & Press Releases 104
Jul 16, 2014: Coherus Announces Initiation Of Phase 3 Trial Of CHS-0214 (Investigational Etanercept Biosimilar) In Chronic Plaque Psoriasis 104
Mar 28, 2012: Lilly's Ixekizumab Met Primary Endpoint In Phase II Study In Patients With Chronic Plaque Psoriasis 104
Nov 24, 2011: Biotest Announces Completion Of Phase IIa Trial Of Tregalizumab In Chronic Plaque Psoriasis 106
Appendix 108
Methodology 108
Coverage 108
Secondary Research 108
Primary Research 108
Expert Panel Validation 108
Contact Us 109
Disclaimer 109

List of Tables
Number of Products under Development for Chronic Plaque Psoriasis, H1 2015 9
Number of Products under Development for Chronic Plaque Psoriasis - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Comparative Analysis by Late Stage Development, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 14
Products under Development by Companies, H1 2015 15
Chronic Plaque Psoriasis - Pipeline by AbGenomics International, Inc., H1 2015 16
Chronic Plaque Psoriasis - Pipeline by Actelion Ltd, H1 2015 17
Chronic Plaque Psoriasis - Pipeline by Almirall, S.A., H1 2015 18
Chronic Plaque Psoriasis - Pipeline by ApoPharma Inc., H1 2015 19
Chronic Plaque Psoriasis - Pipeline by Biotest AG, H1 2015 20
Chronic Plaque Psoriasis - Pipeline by Boehringer Ingelheim GmbH, H1 2015 21
Chronic Plaque Psoriasis - Pipeline by Can-Fite BioPharma Ltd., H1 2015 22
Chronic Plaque Psoriasis - Pipeline by Coherus BioSciences, Inc., H1 2015 23
Chronic Plaque Psoriasis - Pipeline by Covagen AG, H1 2015 24
Chronic Plaque Psoriasis - Pipeline by Eli Lilly and Company, H1 2015 25
Chronic Plaque Psoriasis - Pipeline by GlaxoSmithKline plc, H1 2015 26
Chronic Plaque Psoriasis - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2015 27
Chronic Plaque Psoriasis - Pipeline by Novartis AG, H1 2015 28
Chronic Plaque Psoriasis - Pipeline by OPKO Health, Inc., H1 2015 29
Chronic Plaque Psoriasis - Pipeline by Pfizer Inc., H1 2015 30
Chronic Plaque Psoriasis - Pipeline by Sandoz Inc., H1 2015 31
Chronic Plaque Psoriasis - Pipeline by Sun Pharmaceutical Industries Inc., H1 2015 32
Chronic Plaque Psoriasis - Pipeline by Takeda Pharmaceutical Company Limited, H1 2015 33
Chronic Plaque Psoriasis - Pipeline by UCB S.A., H1 2015 34
Chronic Plaque Psoriasis - Pipeline by XenoPort, Inc., H1 2015 35
Assessment by Monotherapy Products, H1 2015 36
Number of Products by Stage and Target, H1 2015 38
Number of Products by Stage and Mechanism of Action, H1 2015 40
Number of Products by Stage and Route of Administration, H1 2015 42
Number of Products by Stage and Molecule Type, H1 2015 44
Chronic Plaque Psoriasis Therapeutics - Recent Pipeline Updates, H1 2015 80
Chronic Plaque Psoriasis - Dormant Projects, H1 2015 102
Chronic Plaque Psoriasis - Discontinued Products, H1 2015 103